CSPC Pharma Out-Licenses Western Rights for Cancer Drug to Dexcel

CSPC Pharmaceutical Group, headquartered in China's Heibei Province,  has partnered with Dexcel Pharma Technologies to co-develop and commercialize a generic oncology drug in the US, Europe and elsewhere. Dexcel is a privately held Israeli generic drug company, with a presence in more than 30 countries. Dexcel will pay CSPC $2 million to defray the pre-clinical and cGMP compliance certification costs. It will also be liable for up to $5 million in milestones, and Dexcel will be responsible for obtaining approvals of the product. More details.... Stock Symbol: (HK: 1093) Share this with colleagues: // //